Drug Discovery

Bavarian Nordic said the trial will mark the third evaluation of CV301 in combination with a checkpoint inhibitor for oncology indications

Sotagliflozin alliance marks pharma giant's second billion-dollar-plus diabetes collaboration in as many days

Every year, influenza vaccines need to be redesigned due to new strains that may arise or changes because of various mutations and other characteristics. Now, scientists at MIT and the Ragon Institute of MIT, Massachusetts General Hospital, and Harvard report they are working on strategies for designing a universal flu vaccine that could work against any flu strain.

Pharma giant partners with biotechs on cancer treatments and new antibiotics targeting Gram-negative bacteria

Pralsetinib, a selective inhibitor of oncogenic RET alterations, has generated positive clinical results over the past year and is being developed for patients with RET-altered non-small cell lung cancer (NSCLC), various types of thyroid cancer and other solid tumors.

Eli Lilly will partner with Aduro Biotech to develop novel immunotherapies for autoimmune and other inflammatory diseases using Aduro’s cGAS-STING Pathway Inhibitor program, through...

Japanese firm will use Peptide Discovery Platform System to identify macrocyclic peptides against multiple Janssen targets

Deal covers small molecule inhibitors of choline kinase. Enzyme aids tumor survival. Compounds to fight solid and hematological cancers.

Deal has a total value of $1.1 billion and includes five targets.

City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance. Their study provides new insight into how cancer stem cells replenish and visibility into how cancer evades our immune system.